- In March 2025, Schwabe Group acquired a majority stake in Braineffect, strengthening its position in the functional food and supplement market. CEO Olaf Schwabe highlights the brand’s innovation and alignment with Schwabe’s mission for healthier living. Founder Fabian Foelsch remains onboard. This strategic move aims to redefine health in the digital age, expanding Schwabe’s reach and impact
- In April 2024, a clinical trial confirms the efficacy of Silexan, a proprietary lavender oil preparation, in treating mild to moderate depression. In an 8-week study with 498 patients, Silexan showed significant antidepressant effects, comparable to sertraline. These results highlight its potential as a natural treatment option
